21 September 2022, 7:30 CEST - Taipei City, Taiwan and Liege, Belgium - Lotus Pharmaceutical Co., Ltd. (TWSE: 1795, "Lotus") and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA, "Mithra") today are pleased to announce that Estelle®, the first-of-its-kind oral contraceptive with a novel estrogen developed by Mithra, has been approved by both Taiwan Food and Drug Administration (TFDA) and Hong Kong Drug Office, Department of Health, under the trademark ALYSSA®. Through this partnership with Mithra, Lotus will be exclusively marketing the product in Taiwan and Hong Kong.

Read the press release

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 21 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2022 05:39:06 UTC.